Drug
Treprostinil
Status:
Phase 3
Condition:
Other ILD
Intervention Type:
Inhaled Drug
Funder Type:
Industry
Drug Details
Treprostinil delivers antifibrotic and anti-inflammatory effects, which slows down the decline of lung function.
Study Purpose
This is a phase 3, randomized, double-blind, placebo-controlled, and multinational clinical study to evaluate the safety and tolerability of inhaled treprostinil in participants with progressive pulmonary fibrosis (PPF).